Justin Favaro, MD
Hematology & Oncology · Charlotte, NCNPI 1053365320
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.7%.
Across 737 payments — averaging $44.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$4K
- Beone Medicines USA, Inc.$3K
- Sanofi$3K
- Genentech USA, Inc.$2K
- Labcorp Holdings Inc.$2K
- AstraZeneca$2K
- plus $16K from 54 others
Across 422 payments — averaging $2184.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$473K
- GSK$156K
- Novartis$76K
- Regeneron$41K
- E.r. Squibb & Sons, L.L.C.$29K
- Boehringer Ingelheim$26K
- plus $121K from 11 others
What the payments were for
- Consulting fees$12,97040%
- Speaking & faculty fees$2,3957%
- Travel & lodging$130%
- Food & beverage$16,53651%
- Education$6652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,578 in reported general payments places this provider in the 85th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 57 | $736,079 |
| BrukinsaZanubrutinib | 41 | $536,145 |
| PomalystPomalidomide | 21 | $497,879 |
| JakafiRuxolitinib Phosphate | 27 | $458,767 |
| TibsovoIvosidenib | 12 | $398,643 |
| IbrancePalbociclib | 25 | $356,112 |
| CalquenceAcalabrutinib Maleate | 21 | $298,956 |
| CabometyxCabozantinib S-Malate | 11 | $274,530 |
| PemazyrePemigatinib | 14 | $263,893 |
| OxbrytaVoxelotor | 18 | $219,395 |
| XtandiEnzalutamide | 14 | $175,192 |
| VerzenioAbemaciclib | 11 | $166,045 |
| PegasysPeginterferon Alfa-2a | 24 | $106,124 |
| VenclextaVenetoclax | 21 | $93,082 |
| BalversaErdafitinib | 11 | $78,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi, Pemazyre | $349 | $722,66141 claims |
| Beigene USA, Inc.Brukinsa | $218 | $536,14541 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $4,471 | $497,87921 claims |
| Servier Pharmaceuticals LLCTibsovo | $125 | $398,64312 claims |
| PfizerIbrance, Eliquis, Retacrit | $1,180 | $397,89491 claims |
| AstraZenecaCalquence | $1,886 | $298,95621 claims |
| Exelixis Inc.Cabometyx | $236 | $274,53011 claims |
| Astellas Pharma US IncXtandi | $573 | $175,19214 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $327 | $166,58436 claims |
| Genentech, Inc.Pegasys | $55 | $106,12424 claims |
| Johnson & JohnsonBalversa, Xarelto | $1,013 | $105,13643 claims |
| AbbVieVenclexta | $324 | $93,08221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Charlotte
- Shelbi AtrashCharlotte$994K
- Nasfat ShehadehCharlotte$68K
- Jennifer AtlasCharlotte$59K
- Joseph MerrimanCharlotte$50K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.